Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have a great day
Thank you so much
I appreciate your time and help!!
You deserve more than flowers lady boss
1k account is 10x
I’m readyyyyyyyyyy for the next bomb
Thank you!!!!!
My account is very green :)
what a dayyyyyyyyyyyyy
$BNTC: 15.23 BABY !!!!!!!!!!!!!!!!!!!!!!
You better buy the Lady Boss some flowers today
GO $BNTC
Yesssssssssssss
Ezmoneyyyyyyyyyy
$BNTC: $12.10 now............. double that money, right ?
I know you did
Another $1 and I'm up 5digits on the day :)
GO $BNTC
Boooooooooooooom
12.10 now
$BNTC: I got banned on Twitter.............
So i gotta see if I can get a buddy to get me an iHub subscription.
Look at this puppy fly now :)
Watch it hit $30 :)
Saw this happen earlier this year.
GO $BNTC
$BNTC: Now 10.77 !!!!!!!!!!!!!!!
We having fun yet ?
GO $BNTC
Ok
Thanks a lot!!
Pls sign up for twitter so we can private message each.
$BNTC: I'm almost out of posts for the day
Lemme just make sure its primed and ready for you.
Its gonna be a beauty.... and sitting at all time lows
GO $BNTC
Once Bud!!
Which ticker please
I’m ready!!!
$BNTC: Thanks amigo............. lost my subscription
So I can't send private messages anymore.
Will keep on the look out for more.
ACtually............. I found one that you'll love.
Almost as good as our ALGRR play last week :)
GO $BNTC
Doing Beautiful
As I said I get much respect for you
:)
$BNTC: Glad we picked these up so cheaapppppppppp
Look at her ripping now.
We should see about $30 before end of week............. don't you think ?
Just you and me here bro.
No one else knows............ or cares.
MAKIN EZ MONEYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
GO $BNTC
any info on this warrant HCCHW??
got in @6.70
Let goooo
$BNTC: Respect you too bro.... only 1Million float
On a Redomicliation.............. This can FLOAT up real fast if it wants too.
Great Entry here at $6.50 now
GO $BNTC
I’m in Mazinez
Got So much respect for you
$BNTC: Lots of action today............ going to get in
Entering at $6
GO $BNTC
$BNTC: Now $9.20............ impressive move
All day today
$BNTC : Redomiciled back in the US.... taking off $8
Huge move here
Only 1Million FLOAT !!!!!!
https://benitec.com/wp-content/uploads/2020/04/Benitec-Biopharma-Inc-Corporate-Presentation-April-2020-Final-v2.pdf
GO $BNTC
up over 6% today from key chart analysis
halted due to pending news... Does anyone understand this Scheme Meeting thing, and the impact it will have on the stock price today? Australia passed a stimulus, and this thing is super low float... might be a good play today...?
* * $BNTC Video Chart 02-07-2020 * *
Link to Video - click here to watch the technical chart video
News: $BNTC ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report
MELBOURNE, Australia , July 31, 2019 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interfe...
In case you are interested ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report
Update on Oculopharyngeal Muscular Dystrophy Program
Sydney, Australia, 6 June 2019: Benitec Biopharma Limited (“Benitec” or the “Company”) (ASX:BLT;
NASDAQ: BNTC; NASDAQ: BNTCW) today announced the termination of the License and Collaboration
Agreement with Axovant Sciences, as the Benitec team endeavors to conduct several additional
exploratory analyses prior to the initiation of the clinical study in order to potentially improve the
biological efficacy of the compound via further optimization of the proprietary delivery method employed
to dose the target tissues.
Preclinical data derived from recently concluded in vivo evaluations of AXO-AAV-OPMD (formerly
designated as BB-301) in two distinct large animal species suggest that the opportunity exists to further
improve the biological efficacy of the compound via additional optimization of the proprietary delivery
method employed to dose key target tissues that underlie the morbidity and mortality associated with
the progression of Oculopharyngeal Muscular Dystrophy. The initial biological efficacy profile observed
for BB-301 following in vivo testing in the murine model of Oculopharyngeal Muscular Dystrophy,
including full correction of the disease phenotype, remains unchanged. However, the Benitec team
endeavors to conduct several additional exploratory analyses prior to the initiation of clinical testing.
Completion of the experimental work noted above would delay the initiation of the BB-301 clinical study
beyond the timelines that were initially outlined following the execution of the License and
Collaboration Agreement between Benitec Biopharma and Axovant Sciences. As such, the License and
Collaboration Agreement between Benitec Biopharma and Axovant Sciences will be terminated, and all
rights and licenses granted to Axovant Sciences will cease, including the rights to BB-301, which was in
preclinical development for the treatment of Oculopharyngeal Muscular Dystrophy, and all other early
stage research collaboration programs.
The termination of the License and Collaboration Agreement will be effective on September 3, 2019.
Updates will be provided over the coming months regarding the new research programs to be advanced
by the Benitec team.
Good luck and GOD bless,
termination of the License and Collaboration
Trading HALTED pending NEWS
Request for Trading Halt
In accordance with ASX Listing Rule 17.1, Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ:
BNTCW) (Benitec) requests a trading halt of its securities, effective immediately.
For the purposes of the trading halt, Benitec provides the following information:
(a) Benitec is seeking the trading halt as it expects to make an announcement to the ASX in relation to one of its
existing material contracts;
(b) Benitec requests the trading halt be put in place until the earlier of the commencement of trading on Tuesday 11
June 2019, or when an announcement is released to the market; and
(c) Benitec is not aware of any reason why the trading halt should not be granted or of any other information
necessary to inform the market about the trading halt.
Should you have any queries in relation to this trading halt request, please do not hesitate to contact me.
Yours faithfully
Oliver Kidd
Company Secretary
* * $BNTC Video Chart 07-09-18 * *
Link to Video - click here to watch the technical chart video
Agree, news are good but not that good.
Showing a float of less than 6m shares with only 205m outstanding. This could actually jump pretty high and quickly, which we have already seen some of.
5$ already? Gap n trap looks like way to high
Going to be a very interesting day here.
Shares Of Benitec Biopharma Move Higher, Co. Appears To Have Won Patent For Hepatitis B Treatment
2:13 pm ET October 17, 2017 (Benzinga) Print
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9790502.PN.&OS=PN/9790502&RS=PN/9790502
Pannobhaso interviews David Suhy in an in-depth Q&A! https://seekingalpha.com/instablog/19837781-pannobhaso/5052892-magicians-gene-therapy-rnai
Big gain this afternoon! Is something brewing?
Big gain in the afternoon! Is something brewing?
See pages 10, 11, 12, 13, and 14.
https://benitec.com/wp-content/uploads/2017/09/CORPORATEPRESENTATIONATRODMANRENSHAWINVESTMENTCONFERENCE.pdf
Good luck and GOD bless,
George
Followers
|
42
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2207
|
Created
|
01/16/14
|
Type
|
Free
|
Moderators |
Benitec Biopharma’s pipeline of in-house and partnered programs to develop therapeutics for chronic and life-threatening conditions is based on our proprietary technology, DNA-directed RNA(ddRNAi). View our out-licensed programs
Due to its demonstrated ability to effect long-lasting gene silencing, once proven in human trials, ddRNAi technology has significant potential to treat or cure a broad range of human diseases and conditions. These include cancers, neurological diseases, infectious diseases, autoimmune diseases, genetic diseases and other afflictions that are associated with the expression of a small number of key genes.
Our in-house pipeline is summarized below, In-house pipeline
. View our out-licensed programs Out-licensed programs Successful development of therapeutic products in just one of these programs would be a major breakthrough in medical therapy.
Tacere Therapeutics develops human therapeutics based on RNA interference (RNAi) and ddRNAi gene-silencing technology from Benitec Biopharma. Using this approach, the drugs we create promise long term treatment or cure with a single dose.
We target human diseases for which there is currently no effective treatment. Our pipeline includes drugs for Hepatitis C and Age-Related Macular Degeneration.
Tacere Therapeutics is a Benitec Biopharma company.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |